Ceregene and Genzyme Announce Partnership for the Development and Commercialization of CERE-120 for Parkinson's Disease

25-Jun-2007

Ceregene, Inc. and Genzyme Corporation announced that they have entered into a partnership for the development and commercialization of CERE-120, Ceregene's proprietary lead program for the treatment of Parkinson's disease.

Under the terms of the agreement, Genzyme will pay Ceregene a $25 million up-front payment in exchange for certain partnership-related expenses. Ceregene will also be entitled to development-related milestone payments of up to $125 million and 50 percent reimbursement of the worldwide Phase 3 development costs. Genzyme will gain marketing rights in all markets outside of the US and Canada, and Genzyme will pay Ceregene tiered royalties based on sales in markets where it has rights. Ceregene will retain exclusive rights to CERE-120 in the US and Canada.

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and functioning normally. NTN is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease and are responsible for the major motor impairments. CERE-120 is delivered by stereotactic injection to the affected area of the brain, providing stable, long-lasting expression of NTN in a highly targeted fashion.

https://www.bionity.com/en/news/65610/ceregene-and-genzyme-announce-partnership-for-the-development-and-commercialization-of-cere-120-for-parkinson-s-disease.html